Delayed Humira Biosimilar Boosts AbbVie's Fair Value
Pfizer won't be able to access the U.S. market with its biosimilar version until late 2023, providing AbbVie with additional years of exclusivity and strong cash flows.
We are increasing our
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.